587 related articles for article (PubMed ID: 25156255)
1. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
Di Mitri D; Toso A; Chen JJ; Sarti M; Pinton S; Jost TR; D'Antuono R; Montani E; Garcia-Escudero R; Guccini I; Da Silva-Alvarez S; Collado M; Eisenberger M; Zhang Z; Catapano C; Grassi F; Alimonti A
Nature; 2014 Nov; 515(7525):134-7. PubMed ID: 25156255
[TBL] [Abstract][Full Text] [Related]
2. Re: Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
Atala A
J Urol; 2015 Jun; 193(6):2146. PubMed ID: 25986842
[No Abstract] [Full Text] [Related]
3. Re-education of Tumor-Associated Macrophages by CXCR2 Blockade Drives Senescence and Tumor Inhibition in Advanced Prostate Cancer.
Di Mitri D; Mirenda M; Vasilevska J; Calcinotto A; Delaleu N; Revandkar A; Gil V; Boysen G; Losa M; Mosole S; Pasquini E; D'Antuono R; Masetti M; Zagato E; Chiorino G; Ostano P; Rinaldi A; Gnetti L; Graupera M; Martins Figueiredo Fonseca AR; Pereira Mestre R; Waugh D; Barry S; De Bono J; Alimonti A
Cell Rep; 2019 Aug; 28(8):2156-2168.e5. PubMed ID: 31433989
[TBL] [Abstract][Full Text] [Related]
4. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Toso A; Revandkar A; Di Mitri D; Guccini I; Proietti M; Sarti M; Pinton S; Zhang J; Kalathur M; Civenni G; Jarrossay D; Montani E; Marini C; Garcia-Escudero R; Scanziani E; Grassi F; Pandolfi PP; Catapano CV; Alimonti A
Cell Rep; 2014 Oct; 9(1):75-89. PubMed ID: 25263564
[TBL] [Abstract][Full Text] [Related]
5. JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression.
Redmer T; Raigel M; Sternberg C; Ziegler R; Probst C; Lindner D; Aufinger A; Limberger T; Trachtova K; Kodajova P; Högler S; Schlederer M; Stoiber S; Oberhuber M; Bolis M; Neubauer HA; Miranda S; Tomberger M; Harbusch NS; Garces de Los Fayos Alonso I; Sternberg F; Moriggl R; Theurillat JP; Tichy B; Bystry V; Persson JL; Mathas S; Aberger F; Strobl B; Pospisilova S; Merkel O; Egger G; Lagger S; Kenner L
Mol Cancer; 2024 May; 23(1):114. PubMed ID: 38811984
[TBL] [Abstract][Full Text] [Related]
6. Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression.
Garcia AJ; Ruscetti M; Arenzana TL; Tran LM; Bianci-Frias D; Sybert E; Priceman SJ; Wu L; Nelson PS; Smale ST; Wu H
Mol Cell Biol; 2014 Jun; 34(11):2017-28. PubMed ID: 24662052
[TBL] [Abstract][Full Text] [Related]
7.
Parisotto M; Grelet E; El Bizri R; Dai Y; Terzic J; Eckert D; Gargowitsch L; Bornert JM; Metzger D
J Exp Med; 2018 Jun; 215(6):1749-1763. PubMed ID: 29743291
[TBL] [Abstract][Full Text] [Related]
8. Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Guccini I; Revandkar A; D'Ambrosio M; Colucci M; Pasquini E; Mosole S; Troiani M; Brina D; Sheibani-Tezerji R; Elia AR; Rinaldi A; Pernigoni N; Rüschoff JH; Dettwiler S; De Marzo AM; Antonarakis ES; Borrelli C; Moor AE; Garcia-Escudero R; Alajati A; Attanasio G; Losa M; Moch H; Wild P; Egger G; Alimonti A
Cancer Cell; 2021 Jan; 39(1):68-82.e9. PubMed ID: 33186519
[TBL] [Abstract][Full Text] [Related]
9. A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis.
Alimonti A; Nardella C; Chen Z; Clohessy JG; Carracedo A; Trotman LC; Cheng K; Varmeh S; Kozma SC; Thomas G; Rosivatz E; Woscholski R; Cognetti F; Scher HI; Pandolfi PP
J Clin Invest; 2010 Mar; 120(3):681-93. PubMed ID: 20197621
[TBL] [Abstract][Full Text] [Related]
10. Polysaccharide Agaricus blazei Murill stimulates myeloid derived suppressor cell differentiation from M2 to M1 type, which mediates inhibition of tumour immune-evasion via the Toll-like receptor 2 pathway.
Liu Y; Zhang L; Zhu X; Wang Y; Liu W; Gong W
Immunology; 2015 Nov; 146(3):379-91. PubMed ID: 26194418
[TBL] [Abstract][Full Text] [Related]
11. A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.
Kalathur M; Toso A; Chen J; Revandkar A; Danzer-Baltzer C; Guccini I; Alajati A; Sarti M; Pinton S; Brambilla L; Di Mitri D; Carbone G; Garcia-Escudero R; Padova A; Magnoni L; Tarditi A; Maccari L; Malusa F; Kalathur RK; A Pinna L; Cozza G; Ruzzene M; Delaleu N; Catapano CV; Frew IJ; Alimonti A
Nat Commun; 2015 Jun; 6():7227. PubMed ID: 26085373
[TBL] [Abstract][Full Text] [Related]
12. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
Maxwell PJ; Coulter J; Walker SM; McKechnie M; Neisen J; McCabe N; Kennedy RD; Salto-Tellez M; Albanese C; Waugh DJ
Eur Urol; 2013 Aug; 64(2):177-88. PubMed ID: 22939387
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence.
Revandkar A; Perciato ML; Toso A; Alajati A; Chen J; Gerber H; Dimitrov M; Rinaldi A; Delaleu N; Pasquini E; D'Antuono R; Pinton S; Losa M; Gnetti L; Arribas A; Fraering P; Bertoni F; Nepveu A; Alimonti A
Nat Commun; 2016 Dec; 7():13719. PubMed ID: 27941799
[TBL] [Abstract][Full Text] [Related]
14. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression.
Wang G; Lu X; Dey P; Deng P; Wu CC; Jiang S; Fang Z; Zhao K; Konaparthi R; Hua S; Zhang J; Li-Ning-Tapia EM; Kapoor A; Wu CJ; Patel NB; Guo Z; Ramamoorthy V; Tieu TN; Heffernan T; Zhao D; Shang X; Khadka S; Hou P; Hu B; Jin EJ; Yao W; Pan X; Ding Z; Shi Y; Li L; Chang Q; Troncoso P; Logothetis CJ; McArthur MJ; Chin L; Wang YA; DePinho RA
Cancer Discov; 2016 Jan; 6(1):80-95. PubMed ID: 26701088
[TBL] [Abstract][Full Text] [Related]
15. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis.
Chen Z; Trotman LC; Shaffer D; Lin HK; Dotan ZA; Niki M; Koutcher JA; Scher HI; Ludwig T; Gerald W; Cordon-Cardo C; Pandolfi PP
Nature; 2005 Aug; 436(7051):725-30. PubMed ID: 16079851
[TBL] [Abstract][Full Text] [Related]
16. Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.
Yang DR; Ding XF; Luo J; Shan YX; Wang R; Lin SJ; Li G; Huang CK; Zhu J; Chen Y; Lee SO; Chang C
J Biol Chem; 2013 Jun; 288(23):16476-16483. PubMed ID: 23609451
[TBL] [Abstract][Full Text] [Related]
17. Tumor-infiltrating myeloid cells drive senescence evasion and chemoresistance in tumors.
Di Mitri D; Toso A; Alimonti A
Oncoimmunology; 2015 Sep; 4(9):e988473. PubMed ID: 26405613
[TBL] [Abstract][Full Text] [Related]
18. Tumor-derived CXCL8 signaling augments stroma-derived CCL2-promoted proliferation and CXCL12-mediated invasion of PTEN-deficient prostate cancer cells.
Maxwell PJ; Neisen J; Messenger J; Waugh DJ
Oncotarget; 2014 Jul; 5(13):4895-908. PubMed ID: 24970800
[TBL] [Abstract][Full Text] [Related]
19. HIF-α/MIF and NF-κB/IL-6 axes contribute to the recruitment of CD11b+Gr-1+ myeloid cells in hypoxic microenvironment of HNSCC.
Zhu G; Tang Y; Geng N; Zheng M; Jiang J; Li L; Li K; Lei Z; Chen W; Fan Y; Ma X; Li L; Wang X; Liang X
Neoplasia; 2014 Feb; 16(2):168-79. PubMed ID: 24709424
[TBL] [Abstract][Full Text] [Related]
20. Orphan nuclear receptor TLX functions as a potent suppressor of oncogene-induced senescence in prostate cancer via its transcriptional co-regulation of the CDKN1A (p21(WAF1) (/) (CIP1) ) and SIRT1 genes.
Wu D; Yu S; Jia L; Zou C; Xu Z; Xiao L; Wong KB; Ng CF; Chan FL
J Pathol; 2015 May; 236(1):103-15. PubMed ID: 25557355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
